{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:09:48Z","timestamp":1789474188425,"version":"build-2803163510"},"update-to":[{"DOI":"10.1371\/journal.pntd.0009354","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000}}],"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background<\/jats:title><jats:p>Ivermectin is known to cause severe encephalopathies in subjects infected with loiasis, an endemic parasite in Sub-Saharan Africa (SSA). In addition, case reports have described ivermectin-related serious adverse drug reactions (sADRs) such as toxidermias, hepatic and renal disorders. The aim of this study was to identify suspected sADRs reported after ivermectin administration in VigiBase, the World Health Organization\u2019s global individual case safety reports database and analyze their frequency relative to the frequency of these events after other antinematodal drugs reported in SSA and other areas of the world (ROW).<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods<\/jats:title><jats:p>All antinematodal-related sADRs were extracted from VigiBase. Disproportionality analyses were conducted to investigate nervous, cutaneous, psychiatric, respiratory, renal, hepatic and cardiac suspected sADRs reported after ivermectin and benzimidazole drug administration across the world, in SSA and RoW.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Principal findings<\/jats:title><jats:p>2041 post-ivermectin or post-benzimidazole suspected sADRs were identified including 667 after ivermectin exposure (208 in SSA and 459 in the RoW). We found an increased reporting for toxidermias, encephalopathies, confusional disorders after ivermectin compared to benzimidazole drug administration. Encephalopathies were not only reported from SSA but also from the RoW (adjusted reporting odds ratios [aROR] 6.30, 95% confidence interval: 2.68\u201314.8), highlighting the fact these types of sADR occur outside loiasis endemic regions.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Conclusion<\/jats:title><jats:p>We described for the first time suspected sADRs associated with ivermectin exposure according to geographical origin. While our results do not put in question ivermectin\u2019s excellent safety profile, they show that as for all drugs, appropriate pharmacovigilance for adverse reactions is indicated.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pntd.0009354","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T23:26:00Z","timestamp":1618961160000},"page":"e0009354","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":44,"title":["Serious adverse reactions associated with ivermectin: A systematic pharmacovigilance study in sub-Saharan Africa and in the rest of the World"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4400-5204","authenticated-orcid":true,"given":"J\u00e9r\u00e9my T.","family":"Campillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6312-0681","authenticated-orcid":true,"given":"Michel","family":"Boussinesq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9724-4690","authenticated-orcid":true,"given":"S\u00e9bastien","family":"Bertout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0100-4073","authenticated-orcid":true,"given":"Jean-Luc","family":"Faillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8779-977X","authenticated-orcid":true,"given":"C\u00e9dric B.","family":"Chesnais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"key":"pntd.0009354.ref001","unstructured":"ANSM. STROMECTOL 3 mg, comprim\u00e9\u2014R\u00e9sum\u00e9 des caract\u00e9ristiques du produit. [cited 10 Nov 2020]. Available: http:\/\/base-donnees-publique.medicaments.gouv.fr\/affichageDoc.php?specid=61350360&typedoc=R"},{"key":"pntd.0009354.ref002","unstructured":"FDA. Ivermectin prescribing information. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050742s022lbl.pdf"},{"key":"pntd.0009354.ref003","first-page":"9","article-title":"Human onchocerciasis\u2014an overview of the disease","volume":"59","author":"B. Duke","year":"1990","journal-title":"Acta Leiden"},{"key":"pntd.0009354.ref004","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.4049\/jimmunol.144.10.3961","article-title":"Eosinophil degranulation: An immunologic determinant in the pathogenesis of the Mazzotti reaction in human onchocerciasis","volume":"144","author":"SJ Ackerman","year":"1990","journal-title":"J Immunol"},{"issue":"Suppl 1","key":"pntd.0009354.ref005","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/1475-2883-2-S1-S4","article-title":"Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon","volume":"2","author":"M Boussinesq","year":"2003","journal-title":"Filaria J"},{"key":"pntd.0009354.ref006","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0140-6736(96)11094-1","article-title":"Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection","volume":"350","author":"J Gardon","year":"1997","journal-title":"Lancet"},{"key":"pntd.0009354.ref007","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1046\/j.1365-3156.2003.01091.x","article-title":"Variation in incidence of serious adverse events after onchocerciasis treatment with ivermectin in areas of Cameroon co-endemic for loiasis","volume":"8","author":"NAY Twum-Danso","year":"2003","journal-title":"Trop Med Int Heal"},{"key":"pntd.0009354.ref008","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100582","article-title":"Individual risk of post-ivermectin serious adverse events in subjects infected with Loa loa","volume":"28","author":"CB Chesnais","year":"2020","journal-title":"EClinicalMedicine."},{"key":"pntd.0009354.ref009","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s40801-017-0110-0","article-title":"Central and Peripheral Nervous System Disorders Following Ivermectin Mass Administration: A Descriptive Study Based on the Democratic Republic of Congo Pharmacovigilance System","volume":"4","author":"D Nzolo","year":"2017","journal-title":"Drugs\u2014Real World Outcomes"},{"key":"pntd.0009354.ref010","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4269\/ajtmh.17-0042","article-title":"Serious neurological adverse events after ivermectin-do they occur beyond the indication of onchocerciasis?","volume":"98","author":"RE Chandler","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0009354.ref011","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13104-017-2500-5","article-title":"Ivermectin induced Steven-Johnsons syndrome: Case report","volume":"10","author":"D Aroke","year":"2017","journal-title":"BMC Res Notes"},{"key":"pntd.0009354.ref012","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13256-018-1801-1","article-title":"Ivermectin-induced fixed drug eruption in an elderly Cameroonian: A case report","volume":"12","author":"CA Ngwasiri","year":"2018","journal-title":"J Med Case Rep"},{"key":"pntd.0009354.ref013","first-page":"476","article-title":"Drug-induced eruption after treatment of hyperkeratotic crusted scabies with ivermectin","volume":"25","author":"C Mara","year":"2004","journal-title":"Rev Med Interne"},{"key":"pntd.0009354.ref014","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.ad.2017.02.011","article-title":"Treatment of Human Scabies with Oral Ivermectin. Eczematous Eruptions as a New Non-Reported Adverse Event","volume":"108","author":"J Sanz-Navarro","year":"2017","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas English Ed"},{"key":"pntd.0009354.ref015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1272\/jnms.81.157","article-title":"Treatment for Crusted Scabies: Limitations and Side Effects of Treatment with Ivermectin","volume":"81","author":"K Fujimoti","year":"2014","journal-title":"J Nippon Med Sch"},{"key":"pntd.0009354.ref016","first-page":"179","article-title":"Nephropathy and filariasis from Loa loa. Apropos of 1 case of adverse reaction to a dose of ivermectin","volume":"90","author":"T Cruel","year":"1997","journal-title":"Bull Soc Pathol Exot"},{"key":"pntd.0009354.ref017","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1111\/ggi.13158","article-title":"Delirium induced by albendazole\u2013ivermectin combination: Report of the first case in an older patient","volume":"17","author":"U Kaur","year":"2017","journal-title":"Geriatr Gerontol Int"},{"key":"pntd.0009354.ref018","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1089\/cap.2015.0143","article-title":"Drug-Induced Psychosis Associated with Albendazole-Ivermectin Combination Therapy in a 10-Year-Old Child","volume":"25","author":"S Mohapatra","year":"2015","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"pntd.0009354.ref019","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0151-9638(06)71044-4","article-title":"Effets secondaires de l\u2019ivermectine utilis\u00e9e dans le traitement de la gale","volume":"133","author":"A Sparsa","year":"2006","journal-title":"Ann Dermatol Venereol"},{"key":"pntd.0009354.ref020","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.trstmh.2006.02.003","article-title":"First case of ivermectin-induced severe hepatitis","volume":"100","author":"O Veit","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pntd.0009354.ref021","doi-asserted-by":"crossref","first-page":"864","DOI":"10.4269\/ajtmh.16-0259","article-title":"Case report: Multiorgan dysfunction syndrome from Strongyloides stercoralis hyperinfection in a patient with human T-cell lymphotropic virus-1 coinfection after initiation of ivermectin treatment","volume":"95","author":"TT Choksi","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0009354.ref022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0006454","article-title":"Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature","volume":"12","author":"PJ Budge","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009354.ref023","first-page":"707","article-title":"Adverse reactions after large-scale treatment of onchocerciasis with ivermectin: Combined results from eight community trials","volume":"67","author":"G De Sole","year":"1989","journal-title":"Bull World Health Organ"},{"key":"pntd.0009354.ref024","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0035-9203(93)90144-F","article-title":"Adverse reactions to ivermectin treatment for onchocerciasis. Results of a placebo-controlled, double-blind trial in Malawi","volume":"87","author":"GM Burnham","year":"1993","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pntd.0009354.ref025","unstructured":"VigiBase. Uppsala Monitoring Centre. Available: https:\/\/www.who-umc.org\/vigibase\/vigibase\/"},{"key":"pntd.0009354.ref026","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO Global ICSR Database System: Basic facts","volume":"42","author":"M. Lindquist","year":"2008","journal-title":"Drug Inf J"},{"key":"pntd.0009354.ref027","first-page":"1","year":"1998","journal-title":"European Medicines Agency. ICH E2D Post-Approval Safety Data Management"},{"key":"pntd.0009354.ref028","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10618-006-0052-8","article-title":"Duplicate detection in adverse drug reaction surveillance","volume":"14","author":"GN Nor\u00e9n","year":"2007","journal-title":"Data Min Knowl Discov"},{"key":"pntd.0009354.ref029","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"E Brown","year":"1999","journal-title":"Drug Saf"},{"key":"pntd.0009354.ref030","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/pds.1058","article-title":"The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactios","volume":"14","author":"N Moore","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pntd.0009354.ref031","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection on adverse drug reaction spontaneous reporting database of Guangdong province in China","volume":"11","author":"EP van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pntd.0009354.ref032","article-title":"Serious ivermectin toxicity and human ABCB1 nonsense mutations","volume":"383","author":"Baudou Eloise","year":"2020","journal-title":"N Engl J Med"},{"key":"pntd.0009354.ref033","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1001\/jama.288.13.1588","article-title":"Rates of Spontaneous Reporting of Adverse Drug Reactions in France","volume":"288","author":"B B\u00e9gaud","year":"2002","journal-title":"JAMA"},{"key":"pntd.0009354.ref034","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/sim.1157","article-title":"On the assessment of adverse drug reactions from spontaneous reporting systems: The influence of under-reporting on odds ratios","volume":"21","author":"PGM Van Der Heijden","year":"2002","journal-title":"Stat Med"},{"key":"pntd.0009354.ref035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/bmj.317.7151.119","article-title":"Underreporting of suspected adverse drug reactions to newly marketed (\u2019black triangle\u2019) drugs in general practice: Observational study","volume":"317","author":"RM Martin","year":"1998","journal-title":"Br Med J"},{"key":"pntd.0009354.ref036","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40264-015-0351-3","article-title":"An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies","volume":"39","author":"M-A Maci\u00e1-Mart\u00ednez","year":"2016","journal-title":"Drug Saf"},{"key":"pntd.0009354.ref037","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"J-L Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"pntd.0009354.ref038","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3917\/spub.176.0921","article-title":"Plaidoyer pour un renforcement du syst\u00e8me de pharmacovigilance au Burkina Faso","volume":"29","author":"L Kabor\u00e9","year":"2017","journal-title":"Sante Publique (Paris)"},{"issue":"Suppl 1","key":"pntd.0009354.ref039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2883-2-S1-S1","article-title":"Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future","volume":"2","author":"NA Twum-Danso","year":"2003","journal-title":"Filaria J."},{"key":"pntd.0009354.ref040","first-page":"127","article-title":"Ivermectin: a possible neurotoxicity","volume":"5","author":"Anonymous","year":"1991","journal-title":"WHO Drug Inf"},{"key":"pntd.0009354.ref041","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","article-title":"Impact of Safety Alerts on Measures of Disproportionality in Spontaneous Reporting Databases The Notoriety Bias","author":"A Pariente","year":"2007","journal-title":"Drug Saf."},{"key":"pntd.0009354.ref042","article-title":"Embrace of unproven COVID treatment hinders drug trials","author":"ER Mega","journal-title":"Nature"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0009354","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T12:27:19Z","timestamp":1698928039000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009354"}},"subtitle":[],"editor":[{"given":"Samuel","family":"Wanji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0009354","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0009354","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]}}}